On August 12, GENSCRIPT BIO rose 3.1% in regular trading, trading at HK$25.18/share, with turnover of HK$94.83 million, extending its recent strong performance.

On the news front, multiple catalysts continue to support the stock. Associate company Legend Biotech filed its Q2 financials with the U.S. SEC, reporting CARVYKTI Q2 net trade sales of approximately $657 million, up 49.4% year-over-year, with H1 sales reaching $1.254 billion, up 55.1% year-over-year. Meanwhile, global AI-driven drug development has entered a commercialization phase, with U.S.-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO's Life Science division, covering DNA synthesis, protein production, antibody development, and functional validation, reported revenue of $522 million, up 14.8% year-over-year, benefiting from rising AI-driven drug development demand.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)